Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2008-07-21
2011-10-04
Lucas, Zachariah (Department: 1648)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S159100, C424S161100
Reexamination Certificate
active
08029785
ABSTRACT:
The invention provides methods and compositions for the treatment and prevention of a transmittable disease in a subject, such as avians and mammals. The methods and compositions of the invention specifically make use of avian antibodies to the disease to be treated or prevented. Administration of such avian antibodies to a subject has been shown effective for reducing mortality in a population of subjects that are infected, or become infected, with the disease. The invention also provides kits useful for detecting the presence of transmittable diseases in subjects.
REFERENCES:
patent: 3316153 (1967-04-01), Van Frank
patent: 3627873 (1971-12-01), Moyer
patent: 3962421 (1976-06-01), Neurath
patent: 4000257 (1976-12-01), Cano
patent: 4724210 (1988-02-01), Oka et al.
patent: 4748018 (1988-05-01), Stolle et al.
patent: 6682883 (2004-01-01), Monath et al.
patent: 2003/0211110 (2003-11-01), Shimoni et al.
patent: 2004/0009178 (2004-01-01), Bowdish et al.
patent: 2006/0057149 (2006-03-01), Johnson et al.
patent: 2006/0067940 (2006-03-01), Diamond et al.
patent: 19504755 (1996-08-01), None
patent: 152270 (1985-08-01), None
patent: 1371665 (2003-12-01), None
patent: 1552848 (2005-07-01), None
patent: WO-2004/026339 (2004-04-01), None
patent: WO-2004/067035 (2004-08-01), None
Banet-Noach C, Simanov L, Malkinson M. Avian Pathol. Oct. 2003;32(5):489-94.
Srivastava et al. Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design. Expert Rev. Vaccines. 3(4) Suppl. 33-52 (2004).
Cohen. Is an Effective HIV Vaccine Feasible. Science. vol. 30. p. 99 (2005).
Rollier et al. Control of Heterologous Hepatitis C Virus Infection in Chimpanzees is Associated with the Quality of Vaccine-Induced Peripheral T-Helper Immune Response. J Virol. 2004, 78(1): 187-196.
Huang et al. Recent development o therapeutics for chronic HCV infection. Antiviral Res 71 (2006) 351-362.
Berzofsky et al. Progress on new vaccine strategies against chronic viral infections. J Clin Invest. Aug. 2004;114(4):450-62.
Racanelli et al. Presentation of HCV antigens to naive CD8+T cells: why the where, when, what and how are important for virus control and infection outcome. Clin Immunol. Jul. 2007;124(1):5-12.
Malkinson et al. The assay of golsing hepatitis virus and antibody by spermagglutination and spermagglutination-inhibition. Avian Pathology. vol. 3, No. 3,p. 201-204 (1974).
Kris et al. Passive serum antibody causes temporary recovery from influenza virus infection of the nose, trachea and lung of nude mice. Immunology, 1988, 63, p. 349-353.
Agrawal et al., “Human Immunoglobulin as a Treatment for West Nile Virus Infection”,Journal of Infectious Diseases,2003, pp. 1-4, vol. 188, No. 1, Chicago, IL, U.S.A.
Austin et al., “An Outbreak of West Nile Virus—Associated Disease in Domestic Geese (Anser anser domesticus) upon Initial Introduction to a Geographic Region, with Evidence of Bird to Bird Transmission,”Can. Vet. J.,2004, vol. 45, pp. 117-123.
Behn et al., “Use of Polyclonal Avian Antibodies”Chicken Egg Yolk Antibodies, Production and Application,2001, pp. 108-210.
Ben-Nathan et al., “Prophylactic and Therapeutic Efficacy of Human Intravenous Immunoglobulin in Treating West Nile Virus Infection in Mice,”J Infect. Dis.,2003, vol. 188, pp. 5-12.
Carlander, “Avian IgY Antibody:In VitroandIn Vivo,” Acta Universitatis Upsaliensis, Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine, Mar. 6, 2002 (published Ph.D. dissertation, Uppsala University).
Casadevall, “Passive Antibody Administration (Immediate Immunity) as a Specific Defense against Biological Weapons,”Emerging Infectious Diseases,2002, vol. 8(8), pp. 833-841.
Chung et al., “Antibodies against West Nile Virus Nonstructural Protein NS1 Prevent Lethal Infection through FC γ Receptor-Dependent and—Independent Mechanisms,”J. Virol.,2006, vol. 80(3), pp. 1340-1351.
Diamond et al., “A Critical Role for Induced IgM in the Protection against West Nile Virus Infection,”J Exp. Med.,2003, vol. 198(12), pp. 1853-1862.
Engle et al., “Antibody Prophylaxis and Therapy against West Nile Virus Infection in Wild-Type and Immunodeficient Mice,”J. Virol.,2003, vol. 77(24), pp. 12941-12949.
Gea-Banacloche et al., “West Nile Virus: Pathogenesis and Therapeutic Options,”Ann. Intern. Med.,2004, vol. 140(7), pp. 545-554.
Granwehr et al., “West Nile Virus: Where Are We Now?”,Lancet Infectious Diseases,2004, pp. 547-556, vol. 4, No. 9, U.S.A.
Haley et al., “The Role for Intravenous Immunoglobulin in the Treatment of West Nile Virus Encephalitis”, 2003, pp. 88-90, vol. 37, No. 6, Bethesda, MD, U.S.A.
Jackson, “Therapy of West Nile Virus Infection,”Can. J. Neurol. Sci.,2004, vol. 31, pp. 131-134.
Samina et al., “An Inactivated West Nile Virus Vaccine for Domestic Geese—Efficacy Study and a Summary of 4 Years of Field Application,” Vaccine, 2005, pp. 4955-4958, vol. 23, Issue 41.p.
Tesh et al., “Persistent West Nile Virus Infection in the Golden Hamster: Studies on Its Mechanism and Possible Implications for OtherFlavivirusInfections,”J. Infect. Dis.,2005, vol. 192, pp. 287-295.
Throsby et al., “Isolation and Characterization of Human Monoclonal Antibodies from Individuals Infected with West Nile Virus,”J. Virol.,2006, vol. 80(14), pp. 6982-6992.
Weingartl et al., “Comparison of Assays for the Detection of West Nile Virus Antibodies in Chicken Serum,”Canadian Journal of Veterinary Research,2003, pp. 128-132, vol. 47, No. 2.
Xiao et al., “West Nile Virus Infection in the Golden Hamster (Mesocricetus auratus): A Model for West Nile Encephalitis,”Emerging Infectious Diseases,2001, vol. 7(4), pp. 714-721.
Yang et al., “Plaque Reduction Test: an Alternative Method to Assess Specific Antibody Response to pIII-Displayed Peptide of Filamentous Phage M13,”J. Immunol. Methods,2003, vol. 276, pp. 175-183.
Bradley David S.
Brinton Marshall K.
Petell James K.
Schiltz James M.
Avianax, LLC
Horning Michelle S
Lucas Zachariah
Womble Carlyle Sandridge & Rice PLLC
LandOfFree
Therapeutic antibodies for treatment and prophylaxis of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic antibodies for treatment and prophylaxis of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic antibodies for treatment and prophylaxis of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4279601